compound semaglutide deaths reduces risk of all-cause death Compounded Semaglutide: What to Know
Description
If FDA approves in 2027, UK availability could come in late 2027 or early 2028
This can be one of the more difficult side effects to overcome, especially early in treatment
Implications for the GLP-1 market: More employers will get ahead of the high costs associated with rising GLP-1 use by significantly restricting or eliminating coverage for the drugs, particularly as new oral formulations broaden their appeal
doi: 10.1016/j.bbrc.2017.11.076
